LEGN Legend Biotech Corp IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1801198 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q3*2024-09-30 | 2024Q2*2024-06-30 | 2024Q12024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $306.38M | $272.33M | $255.06M | $195.05M | $186.58M | $160.21M | $186.52M | $93.99M |
| Cost of revenue | $119.47M | $113.26M | $94.87M | $69.50M | $69.40M | $52.51M | $45.35M | $49.10M |
| Gross profit | $186.91M | $159.07M | $160.19M | $125.56M | $117.18M | $107.69M | $141.17M | $44.89M |
| R&D expense | $101.33M | $113.15M | $98.30M | $101.92M | $104.43M | $95.52M | $112.63M | $100.96M |
| Operating income | -$19.63M | -$43.45M | — | — | -$79.31M | -$70.36M | — | — |
| Interest expense | $5.48M | $5.64M | $5.22M | $5.06M | $5.15M | $5.50M | $5.48M | $5.47M |
| Pretax income | -$19.60M | -$39.07M | -$124.80M | -$99.13M | $40.51M | -$120.89M | -$17.97M | -$59.79M |
| Income tax | $11.22M | $616,000 | $582,000 | $1.79M | $14.23M | $4.43M | $226,000 | $5,000 |
| Net income | -$30.82M | -$39.69M | -$125.38M | -$100.92M | $26.28M | -$125.32M | -$18.20M | -$59.79M |
| EPS (basic) | — | -0.11 | -0.34 | -0.27 | — | -0.34 | -0.05 | -0.16 |
| EPS (diluted) | — | -0.11 | -0.34 | -0.27 | — | -0.34 | -0.05 | -0.16 |
| Weighted avg. shares (diluted) | — | 369.27M | 368.27M | — | — | 366.56M | 365.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $901.90M | $278.89M | $266.59M | $441.70M | $286.70M | $459.28M | $201.25M | $897.57M |
| Receivables | $13.10M | $1.24M | $27.58M | $369,000 | $6.40M | $705,000 | $13.06M | $3.31M |
| Inventory | $32.00M | $29.18M | $35.59M | $30.93M | $23.90M | $23.55M | $18.87M | $22.15M |
| Current assets | $1.25B | $1.24B | $1.25B | $1.22B | $1.28B | $1.35B | $1.42B | $1.41B |
| PP&E, netmay include right-of-use assets (IFRS) | $116.30M | $111.40M | $106.38M | $98.81M | $99.30M | $104.03M | $105.02M | $105.28M |
| Intangibles | $1.90M | — | $2.14M | $2.08M | $2.20M | $2.51M | $2.77M | $3.15M |
| Total assets | $1.73B | $1.71B | $1.69B | $1.62B | $1.67B | $1.74B | $1.80B | $1.78B |
| Current liabilities | $636.40M | $433.57M | $265.48M | $234.37M | $277.70M | $270.89M | $294.30M | $249.68M |
| Short-term debt | $319.10M | $142.87M | — | — | $0 | — | — | — |
| Long-term debt | $0 | $171.93M | $310.26M | $305.75M | $301.20M | $296.62M | $291.56M | $286.40M |
| Total debt | $319.10M | $314.80M | $310.26M | $305.75M | $301.20M | $296.62M | $291.56M | $286.40M |
| Total liabilities | $731.60M | $701.69M | $654.38M | $597.90M | $629.60M | $619.72M | $639.18M | $611.05M |
| Shareholders' equity | $1.00B | $1.01B | $1.04B | $1.02B | $1.04B | $1.12B | $1.16B | $1.16B |
| Net debt | -$582.80M | $35.91M | $43.68M | -$135.96M | $14.50M | -$162.65M | $90.31M | -$611.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.21M | $28.80M | -$13.04M | -$103.75M | -$82.08M | -$75.82M | -$1.65M | $15.52M |
| Capital expenditure | $12.37M | $5.00M | $9.22M | $2.00M | $2.38M | $2.06M | $3.42M | $6.24M |
| Free cash flow | -$24.57M | $23.80M | -$22.27M | -$105.76M | -$84.46M | -$77.89M | -$5.07M | $9.28M |
| Investing cash flow | $638.49M | -$20.00M | -$165.53M | $256.64M | -$87.84M | $329.08M | -$695.63M | -$396.15M |
| Financing cash flow | -$647,000 | $670,000 | -$990,000 | $667,000 | -$333,000 | $4.25M | $955,000 | $831,000 |
| Stock-based compensation | $14.94M | $15.02M | $18.70M | $15.95M | $13.39M | $15.11M | $21.74M | $18.70M |
Free plan shows the latest 8 periods; Pro shows all 14 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.